| scholarly article | Q13442814 |
| P50 | author | Jeffrey A Bluestone | Q87186905 |
| P2093 | author name string | Arabella Young | |
| Zoe Quandt | |||
| P2860 | cites work | The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice | Q24670319 |
| Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor | Q28144319 | ||
| Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice | Q28201627 | ||
| Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 | Q28284177 | ||
| Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 | Q29619280 | ||
| Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination | Q30251438 | ||
| Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis | Q33607108 | ||
| Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors | Q33707098 | ||
| Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape | Q34241893 | ||
| PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice | Q34577678 | ||
| Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes | Q35107621 | ||
| Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. | Q35669414 | ||
| Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota | Q35833921 | ||
| Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis | Q35912366 | ||
| Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. | Q50626424 | ||
| β Cells that Resist Immunological Attack Develop during Progression of Autoimmune Diabetes in NOD Mice. | Q50897119 | ||
| Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity. | Q50974735 | ||
| Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. | Q52615452 | ||
| Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. | Q52649833 | ||
| Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small cell lung cancer. | Q52721675 | ||
| Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. | Q52729451 | ||
| Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. | Q54215187 | ||
| Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. | Q55421471 | ||
| Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis | Q56892731 | ||
| Bispecific antibodies in cancer immunotherapy | Q56893015 | ||
| Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody | Q56896949 | ||
| Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity | Q57160066 | ||
| Infliximab for IPILIMUMAB-Related Colitis--Letter | Q58025377 | ||
| CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. | Q64950601 | ||
| Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells | Q88885438 | ||
| Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors | Q89224295 | ||
| High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma | Q89429146 | ||
| Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma | Q36061606 | ||
| The NOD mouse: a model of immune dysregulation | Q36072434 | ||
| Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. | Q36228158 | ||
| Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes | Q36400199 | ||
| Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events | Q36798441 | ||
| Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities | Q37369239 | ||
| Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center | Q37380454 | ||
| Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes | Q37565259 | ||
| Fulminant Myocarditis with Combination Immune Checkpoint Blockade | Q37595462 | ||
| Clinical applications of diabetes antibody testing | Q37624232 | ||
| Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis | Q38326290 | ||
| Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. | Q38440279 | ||
| Is autoimmunity the Achilles' heel of cancer immunotherapy? | Q38687375 | ||
| Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer. | Q38752932 | ||
| Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy | Q38801519 | ||
| Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. | Q38837469 | ||
| The future of cancer treatment: immunomodulation, CARs and combination immunotherapy | Q38875355 | ||
| Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. | Q38883332 | ||
| Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. | Q38916367 | ||
| Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma | Q39031722 | ||
| Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review | Q39387413 | ||
| Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab | Q40262479 | ||
| Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer | Q40414975 | ||
| Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. | Q40534742 | ||
| HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis | Q40596434 | ||
| Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report | Q41018488 | ||
| Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells | Q43448621 | ||
| T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. | Q44384732 | ||
| Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series | Q45839919 | ||
| Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire | Q46177852 | ||
| Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group | Q47102520 | ||
| Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer | Q47252798 | ||
| Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. | Q47447695 | ||
| Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. | Q47681829 | ||
| Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. | Q47919775 | ||
| Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. | Q48241683 | ||
| The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. | Q48306869 | ||
| Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors | Q48373246 | ||
| Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapy. | Q49720370 | ||
| Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. | Q49788993 | ||
| Early B cell changes predict autoimmunity following combination immune checkpoint blockade | Q50140526 | ||
| P433 | issue | 12 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 1445-1452 | |
| P577 | publication date | 2018-12-01 | |
| P1433 | published in | Cancer Immunology Research | Q26841983 |
| P1476 | title | The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy | |
| P478 | volume | 6 |
| Q91928619 | Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect |
| Q92166689 | Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases |
| Q94526283 | Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy |
| Q89528381 | Febrile Neutropenia in a Patient with Non-Small Cell Lung Cancer Treated with the Immune-Checkpoint Inhibitor Nivolumab |
| Q89571050 | Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes |
| Q101059655 | Immune-related adverse events of a PD-(L)1 inhibitor plus chemotherapy versus a PD-(L)1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials |
| Q94550478 | Immune-related adverse events of checkpoint inhibitors |
| Q64073978 | Is the onset of adverse effects of immunotherapy always bad news for the patients…?-certainly not! |
| Q91660706 | Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition |
| Q90293059 | Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon |
| Q90537868 | Protein Kinase C-η Deficiency Does Not Impair Antiviral Immunity and CD8+ T Cell Activation |
| Q98735502 | Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies |
| Q89976335 | Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications |
| Q64923698 | Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials. |
| Q91329987 | The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma |
| Q91768573 | Treg cell-based therapies: challenges and perspectives |
Search more.